首页 › 骨髓增生异常综合征 › 俄亥俄州 › Columbus
Columbus OH 骨髓增生异常综合征临床试验
14项针对 骨髓增生异常综合征的研究正在 Columbus及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
招募中1/2 期
- The Ohio State University, Columbus
Collection of Tissue Samples for Cancer Research
招募中观察性研究
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
招募中1 期
- Ohio State University, The James Comprehensive Cancer, Columbus
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Nationwide Children's Hospital, Columbus
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
招募中1/2 期
- The Ohio State University Comprehensive Cancer Center, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
招募中1 期
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
招募中1 期
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
招募中观察性研究
- The Ohio State University Medical Center, Columbus
其他城市的 骨髓增生异常综合征试验
- Houston, TX43 项研究
- Baldwin Park, CA26 项研究
- New York City, NY21 项研究
- Seattle, WA21 项研究
- Washington, DC20 项研究
- Boston, MA19 项研究
- Tampa, FL19 项研究
- Miami, FL17 项研究
- Durham, NC14 项研究
- Chicago, IL13 项研究
- Atlanta, GA13 项研究
- St. Louis, MO13 项研究
Columbus的其他研究
- 非小细胞肺癌56 项研究
- 乳腺癌39 项研究
- 卵巢癌39 项研究
- 癌症（所有类型）38 项研究
- 肺癌37 项研究
- 急性髓系白血病35 项研究
- 慢性淋巴细胞白血病28 项研究
- 转移性癌症27 项研究
- 子宫内膜癌25 项研究
- 结直肠癌24 项研究
- 前列腺癌24 项研究
- 多发性骨髓瘤24 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。